Role of endothelial dysfunction in atherosclerosis
- PMID: 15198963
- DOI: 10.1161/01.CIR.0000131515.03336.f8
Role of endothelial dysfunction in atherosclerosis
Abstract
As the major regulator of vascular homeostasis, the endothelium exerts a number of vasoprotective effects, such as vasodilation, suppression of smooth muscle cell growth, and inhibition of inflammatory responses. Many of these effects are largely mediated by nitric oxide, the most potent endogenous vasodilator. Nitric oxide opposes the effects of endothelium-derived vasoconstrictors and inhibits oxidation of low-density lipoprotein. A defect in the production or activity of nitric oxide leads to endothelial dysfunction, signaled by impaired endothelium-dependent vasodilation. Accumulating evidence suggests that endothelial dysfunction is an early marker for atherosclerosis and can be detected before structural changes to the vessel wall are apparent on angiography or ultrasound. Many of the risk factors that predispose to atherosclerosis can also cause endothelial dysfunction, and the presence of multiple risk factors has been found to predict endothelial dysfunction. A number of clinical trials have shown that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) improve endothelial dysfunction in patients with coronary risk factors beyond what could be attributed to their impact on plasma lipids. Studies have elucidated several possible mechanisms by which statin therapy may improve endothelial dysfunction, including upregulation of nitric oxide production or activity and reduction of oxidative stress.
Similar articles
-
Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.Circ Res. 2004 Jul 23;95(2):217-23. doi: 10.1161/01.RES.0000134628.96682.9b. Epub 2004 Jun 3. Circ Res. 2004. PMID: 15178637 Free PMC article. Clinical Trial.
-
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction.Endothelium. 2003;10(1):17-21. doi: 10.1080/10623320303355. Endothelium. 2003. PMID: 12699073 Review.
-
Statins and endothelial dysfunction.Semin Vasc Med. 2004 Nov;4(4):333-46. doi: 10.1055/s-2004-869590. Semin Vasc Med. 2004. PMID: 15861315 Review.
-
[Change of endothelial function with aging].Nihon Rinsho. 2005 Jun;63(6):989-93. Nihon Rinsho. 2005. PMID: 15948380 Review. Japanese.
-
Effects of statins on endothelium and signaling mechanisms.Stroke. 2004 Nov;35(11 Suppl 1):2708-11. doi: 10.1161/01.STR.0000143319.73503.38. Epub 2004 Sep 16. Stroke. 2004. PMID: 15375300 Review.
Cited by
-
Efficacy of Colchicine for Prevention of Stroke and Adverse Cardiovascular Events: A Meta-analysis of 16 Randomized Controlled Trials.Am J Cardiovasc Drugs. 2025 Jan;25(1):83-93. doi: 10.1007/s40256-024-00689-7. Epub 2024 Oct 26. Am J Cardiovasc Drugs. 2025. PMID: 39460903
-
Interrelationships between obesity, obstructive sleep apnea syndrome and cardiovascular risk in obese adolescents.Int J Obes (Lond). 2015 Jul;39(7):1086-93. doi: 10.1038/ijo.2015.67. Epub 2015 May 18. Int J Obes (Lond). 2015. PMID: 25913504 Free PMC article.
-
Exercise during pregnancy mitigates the adverse effects of maternal obesity on adult male offspring vascular function and alters one-carbon metabolism.Physiol Rep. 2020 Sep;8(18):e14582. doi: 10.14814/phy2.14582. Physiol Rep. 2020. PMID: 32975908 Free PMC article.
-
Artemisinin inhibits monocyte adhesion to HUVECs through the NF-κB and MAPK pathways in vitro.Int J Mol Med. 2016 Jun;37(6):1567-75. doi: 10.3892/ijmm.2016.2579. Epub 2016 Apr 26. Int J Mol Med. 2016. PMID: 27122190 Free PMC article.
-
Arterial elasticity, endothelial function and intracranial vascular health: A multimodal MRI study.J Cereb Blood Flow Metab. 2021 Jun;41(6):1390-1397. doi: 10.1177/0271678X20956950. Epub 2020 Oct 20. J Cereb Blood Flow Metab. 2021. PMID: 33081567 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials